

# Double Barreled Antibodies Drug-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/DC10AA2C2FFEN.html>

Date: February 2018

Pages: 141

Price: US\$ 3,480.00 (Single User License)

ID: DC10AA2C2FFEN

## Abstracts

### Report Summary

Double Barreled Antibodies Drug-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Double Barreled Antibodies Drug industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Double Barreled Antibodies Drug 2013-2017, and development forecast 2018-2023

Main market players of Double Barreled Antibodies Drug in EMEA, with company and product introduction, position in the Double Barreled Antibodies Drug market

Market status and development trend of Double Barreled Antibodies Drug by types and applications

Cost and profit status of Double Barreled Antibodies Drug, and marketing status

Market growth drivers and challenges

The report segments the EMEA Double Barreled Antibodies Drug market as:

EMEA Double Barreled Antibodies Drug Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA Double Barreled Antibodies Drug Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Removab  
BLINCYTO  
Others

EMEA Double Barreled Antibodies Drug Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Lung Cancer  
Brain Cancer  
Liver Cancer  
Others

EMEA Double Barreled Antibodies Drug Market: Players Segment Analysis (Company and Product introduction, Double Barreled Antibodies Drug Sales Volume, Revenue, Price and Gross Margin):

Amgen Inc.  
F. Hoffman La Roche Ltd.  
AbbVie Inc.  
OncoMed Pharmaceuticals, Inc.  
Glenmark Pharmaceuticals Limited  
Xencor, Inc.  
MacroGenics, Inc.  
Aptevo Therapeutics Inc.  
Ligand Pharmaceuticals, Inc.  
Regeneron Pharmaceuticals, Inc.  
Fresenius SE & Co. KGaA  
Merus N.V.

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF DOUBLE BARRELED ANTIBODIES DRUG**

- 1.1 Definition of Double Barreled Antibodies Drug in This Report
- 1.2 Commercial Types of Double Barreled Antibodies Drug
  - 1.2.1 Removab
  - 1.2.2 BLINCYTO
  - 1.2.3 Others
- 1.3 Downstream Application of Double Barreled Antibodies Drug
  - 1.3.1 Lung Cancer
  - 1.3.2 Brain Cancer
  - 1.3.3 Liver Cancer
  - 1.3.4 Others
- 1.4 Development History of Double Barreled Antibodies Drug
- 1.5 Market Status and Trend of Double Barreled Antibodies Drug 2013-2023
  - 1.5.1 EMEA Double Barreled Antibodies Drug Market Status and Trend 2013-2023
  - 1.5.2 Regional Double Barreled Antibodies Drug Market Status and Trend 2013-2023

### **CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Double Barreled Antibodies Drug in EMEA 2013-2017
- 2.2 Consumption Market of Double Barreled Antibodies Drug in EMEA by Regions
  - 2.2.1 Consumption Volume of Double Barreled Antibodies Drug in EMEA by Regions
  - 2.2.2 Revenue of Double Barreled Antibodies Drug in EMEA by Regions
- 2.3 Market Analysis of Double Barreled Antibodies Drug in EMEA by Regions
  - 2.3.1 Market Analysis of Double Barreled Antibodies Drug in Europe 2013-2017
  - 2.3.2 Market Analysis of Double Barreled Antibodies Drug in Middle East 2013-2017
  - 2.3.3 Market Analysis of Double Barreled Antibodies Drug in Africa 2013-2017
- 2.4 Market Development Forecast of Double Barreled Antibodies Drug in EMEA 2018-2023
  - 2.4.1 Market Development Forecast of Double Barreled Antibodies Drug in EMEA 2018-2023
  - 2.4.2 Market Development Forecast of Double Barreled Antibodies Drug by Regions 2018-2023

### **CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES**

- 3.1 Whole EMEA Market Status by Types

- 3.1.1 Consumption Volume of Double Barreled Antibodies Drug in EMEA by Types
- 3.1.2 Revenue of Double Barreled Antibodies Drug in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries
  - 3.2.1 Market Status by Types in Europe
  - 3.2.2 Market Status by Types in Middle East
  - 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Double Barreled Antibodies Drug in EMEA by Types

## **CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

- 4.1 Demand Volume of Double Barreled Antibodies Drug in EMEA by Downstream Industry
- 4.2 Demand Volume of Double Barreled Antibodies Drug by Downstream Industry in Major Countries
  - 4.2.1 Demand Volume of Double Barreled Antibodies Drug by Downstream Industry in Europe
  - 4.2.2 Demand Volume of Double Barreled Antibodies Drug by Downstream Industry in Middle East
  - 4.2.3 Demand Volume of Double Barreled Antibodies Drug by Downstream Industry in Africa
- 4.3 Market Forecast of Double Barreled Antibodies Drug in EMEA by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF DOUBLE BARRELED ANTIBODIES DRUG**

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Double Barreled Antibodies Drug Downstream Industry Situation and Trend Overview

## **CHAPTER 6 DOUBLE BARRELED ANTIBODIES DRUG MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA**

- 6.1 Sales Volume of Double Barreled Antibodies Drug in EMEA by Major Players
- 6.2 Revenue of Double Barreled Antibodies Drug in EMEA by Major Players
- 6.3 Basic Information of Double Barreled Antibodies Drug by Major Players
  - 6.3.1 Headquarters Location and Established Time of Double Barreled Antibodies Drug Major Players

6.3.2 Employees and Revenue Level of Double Barreled Antibodies Drug Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

## **CHAPTER 7 DOUBLE BARRELED ANTIBODIES DRUG MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

7.1 Amgen Inc.

7.1.1 Company profile

7.1.2 Representative Double Barreled Antibodies Drug Product

7.1.3 Double Barreled Antibodies Drug Sales, Revenue, Price and Gross Margin of Amgen Inc.

7.2 F. Hoffman La Roche Ltd.

7.2.1 Company profile

7.2.2 Representative Double Barreled Antibodies Drug Product

7.2.3 Double Barreled Antibodies Drug Sales, Revenue, Price and Gross Margin of F. Hoffman La Roche Ltd.

7.3 AbbVie Inc.

7.3.1 Company profile

7.3.2 Representative Double Barreled Antibodies Drug Product

7.3.3 Double Barreled Antibodies Drug Sales, Revenue, Price and Gross Margin of AbbVie Inc.

7.4 OncoMed Pharmaceuticals, Inc.

7.4.1 Company profile

7.4.2 Representative Double Barreled Antibodies Drug Product

7.4.3 Double Barreled Antibodies Drug Sales, Revenue, Price and Gross Margin of OncoMed Pharmaceuticals, Inc.

7.5 Glenmark Pharmaceuticals Limited

7.5.1 Company profile

7.5.2 Representative Double Barreled Antibodies Drug Product

7.5.3 Double Barreled Antibodies Drug Sales, Revenue, Price and Gross Margin of Glenmark Pharmaceuticals Limited

7.6 Xencor, Inc.

7.6.1 Company profile

7.6.2 Representative Double Barreled Antibodies Drug Product

7.6.3 Double Barreled Antibodies Drug Sales, Revenue, Price and Gross Margin of

Xencor, Inc.

7.7 MacroGenics, Inc.

7.7.1 Company profile

7.7.2 Representative Double Barreled Antibodies Drug Product

7.7.3 Double Barreled Antibodies Drug Sales, Revenue, Price and Gross Margin of MacroGenics, Inc.

7.8 Aptevo Therapeutics Inc.

7.8.1 Company profile

7.8.2 Representative Double Barreled Antibodies Drug Product

7.8.3 Double Barreled Antibodies Drug Sales, Revenue, Price and Gross Margin of Aptevo Therapeutics Inc.

7.9 Ligand Pharmaceuticals, Inc.

7.9.1 Company profile

7.9.2 Representative Double Barreled Antibodies Drug Product

7.9.3 Double Barreled Antibodies Drug Sales, Revenue, Price and Gross Margin of Ligand Pharmaceuticals, Inc.

7.10 Regeneron Pharmaceuticals, Inc.

7.10.1 Company profile

7.10.2 Representative Double Barreled Antibodies Drug Product

7.10.3 Double Barreled Antibodies Drug Sales, Revenue, Price and Gross Margin of Regeneron Pharmaceuticals, Inc.

7.11 Fresenius SE & Co. KGaA

7.11.1 Company profile

7.11.2 Representative Double Barreled Antibodies Drug Product

7.11.3 Double Barreled Antibodies Drug Sales, Revenue, Price and Gross Margin of Fresenius SE & Co. KGaA

7.12 Merus N.V.

7.12.1 Company profile

7.12.2 Representative Double Barreled Antibodies Drug Product

7.12.3 Double Barreled Antibodies Drug Sales, Revenue, Price and Gross Margin of Merus N.V.

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF DOUBLE BARRELED ANTIBODIES DRUG**

8.1 Industry Chain of Double Barreled Antibodies Drug

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF DOUBLE BARRELED ANTIBODIES DRUG**

- 9.1 Cost Structure Analysis of Double Barreled Antibodies Drug
- 9.2 Raw Materials Cost Analysis of Double Barreled Antibodies Drug
- 9.3 Labor Cost Analysis of Double Barreled Antibodies Drug
- 9.4 Manufacturing Expenses Analysis of Double Barreled Antibodies Drug

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF DOUBLE BARRELED ANTIBODIES DRUG**

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
  - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

- 12.1 Methodology/Research Approach
  - 12.1.1 Research Programs/Design
  - 12.1.2 Market Size Estimation
  - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
  - 12.2.1 Secondary Sources
  - 12.2.2 Primary Sources
- 12.3 Reference

## I would like to order

Product name: Double Barreled Antibodies Drug-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/DC10AA2C2FFEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DC10AA2C2FFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970